Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Bird

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
The Journal of Allergy and Clinical Immunology|May 30, 2025
Introduction of allergenic foods after treatment with omalizumabJennifer Dantzer, Yamini Virkud, Julie Wang, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2025
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergiesR Sharon Chinthrajah, Michael Kulis, Stacie M Jones, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 1, 2025
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The New England Journal of Medicine|February 26, 2024
Omalizumab for the Treatment of Multiple Food AllergiesRobert A Wood, Alkis Togias, Scott H Sicherer, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 1, 2021
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial ResultsJacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2020
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year resultsDavid M Fleischer, Wayne G Shreffler, Dianne E Campbell, et al.
Clinical and Translational Allergy|November 29, 2024
10 practical priorities to prevent and manage serious allergic reactions: GA<sup>2</sup>LEN ANACare and EFA Anaphylaxis ManifestoAntonella Muraro, Debra de Silva, Marcia Podesta, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 28, 2020
Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On StudyBrian P Vickery, Andrea Vereda, Caroline Nilsson, et al.
The New England Journal of Medicine|November 20, 2018
AR101 Oral Immunotherapy for Peanut Allergy, Brian P Vickery, Andrea Vereda, et al.
Clinical and Translational Allergy|May 21, 2025
Towards a common approach for managing food allergy and serious allergic reactions (anaphylaxis) at school. GA<sup>2</sup>LEN and EFA consensus statementAntoine Deschildre, Montserrat Alvaro-Lozano, Antonella Muraro, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
The Journal of Allergy and Clinical Immunology|May 30, 2025
Introduction of allergenic foods after treatment with omalizumabJennifer Dantzer, Yamini Virkud, Julie Wang, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2025
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergiesR Sharon Chinthrajah, Michael Kulis, Stacie M Jones, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 1, 2025
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The New England Journal of Medicine|February 26, 2024
Omalizumab for the Treatment of Multiple Food AllergiesRobert A Wood, Alkis Togias, Scott H Sicherer, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 1, 2021
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial ResultsJacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2020
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year resultsDavid M Fleischer, Wayne G Shreffler, Dianne E Campbell, et al.
Clinical and Translational Allergy|November 29, 2024
10 practical priorities to prevent and manage serious allergic reactions: GA<sup>2</sup>LEN ANACare and EFA Anaphylaxis ManifestoAntonella Muraro, Debra de Silva, Marcia Podesta, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 28, 2020
Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On StudyBrian P Vickery, Andrea Vereda, Caroline Nilsson, et al.
The New England Journal of Medicine|November 20, 2018
AR101 Oral Immunotherapy for Peanut Allergy, Brian P Vickery, Andrea Vereda, et al.
Clinical and Translational Allergy|May 21, 2025
Towards a common approach for managing food allergy and serious allergic reactions (anaphylaxis) at school. GA<sup>2</sup>LEN and EFA consensus statementAntoine Deschildre, Montserrat Alvaro-Lozano, Antonella Muraro, et al.
Pageof 14